Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 5,115 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 5,115 shares of the company’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $40.05, for a total value of $204,855.75. Following the completion of the transaction, the insider owned 45,822 shares of the company’s stock, valued at $1,835,171.10. The trade was a 10.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Castle Biosciences Stock Performance

NASDAQ:CSTL opened at $39.94 on Thursday. The firm’s 50 day moving average is $27.40 and its two-hundred day moving average is $21.95. Castle Biosciences, Inc. has a fifty-two week low of $14.59 and a fifty-two week high of $40.51. The company has a quick ratio of 6.31, a current ratio of 6.47 and a debt-to-equity ratio of 0.02. The company has a market cap of $1.17 billion, a P/E ratio of -88.76 and a beta of 1.12.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.32. The firm had revenue of $80.55 million for the quarter, compared to the consensus estimate of $71.06 million. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. Castle Biosciences has set its FY 2025 guidance at EPS. Analysts expect that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CSTL. Franklin Resources Inc. raised its holdings in shares of Castle Biosciences by 0.5% during the third quarter. Franklin Resources Inc. now owns 99,787 shares of the company’s stock valued at $2,272,000 after buying an additional 540 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Castle Biosciences by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock valued at $309,000 after purchasing an additional 655 shares during the period. Envestnet Asset Management Inc. raised its stake in shares of Castle Biosciences by 1.0% during the second quarter. Envestnet Asset Management Inc. now owns 70,478 shares of the company’s stock valued at $1,439,000 after purchasing an additional 707 shares in the last quarter. Inspire Investing LLC lifted its holdings in Castle Biosciences by 4.0% in the third quarter. Inspire Investing LLC now owns 19,887 shares of the company’s stock worth $453,000 after purchasing an additional 770 shares during the period. Finally, CWM LLC grew its position in Castle Biosciences by 80.6% in the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock valued at $44,000 after buying an additional 853 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on CSTL shares. Wall Street Zen upgraded Castle Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 10th. Weiss Ratings reissued a “sell (d)” rating on shares of Castle Biosciences in a research report on Tuesday. BTIG Research lifted their price objective on shares of Castle Biosciences from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Canaccord Genuity Group reissued a “buy” rating and set a $37.00 target price on shares of Castle Biosciences in a report on Tuesday, September 9th. Finally, Zacks Research upgraded shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.43.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.